Hypercoagulability biomarkers in Trypanosoma cruzi-infected patients

Thrombosis and Haemostasis

Volumn 106, Issue 4, 2011, Pages 617-623

  Pinazo, María Jesús ^a   Tassies, Dolors ^b   Muñoz, José ^a   Fisa, Roser ^a   de Jesús, Elizabeth ^a   Monteagudo, Juan ^b   Ayala, Edgar ^c   Gállego, Montserrat ^a   Reverter, Joan Carles ^b   Gascon, Joaquim ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Biomarkers; Chagas disease; Endogenous thrombin potential; Hypercoagulability; Prothrombin fragment 1+2

Indexed keywords

ANTIPLASMIN; ANTITHROMBIN; BENZNIDAZOLE; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; PADGEM PROTEIN; PLASMIN; PLASMIN ANTIPLASMIN COMPLEX; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN FRAGMENT 1-2; TISSUE TYPE PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOGENOUS THROMBIN POTENTIAL; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOEMBOLISM; TRYPANOSOMA CRUZI;

ADULT; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROTHROMBIN; RISK; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; TRYPANOSOMA CRUZI;

EID: 80053186374     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0251     Document Type: Article

References (38)

1. Pan American Health Organization. Estimación cuantitativa de la enfermedad de Chagas en las Americas. Organización Panamericana de la Salud, Montevideo, Uruguay, 2006.
2. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010; 115: 22-27.
3. Punukollu G, Gowda RM, Khan IA, et al. Clinical aspects of the Chagas' heart disease. Int J Cardiol 2007; 115: 279-283.
4. Carod-Artal FJ, Vargas AP, Horan TA, et al. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 2005; 36: 965-970.
5. Carod-Artal FJ. Chagas cardiomyopathy and ischemic stroke. Expert Rev Cardiovasc Ther 2006; 4: 119-130.
6. Andrade ZA, Sadigurski M. Trombo-embolismo command post chagásicos sem cardiac insuficiência. Gaz Med Bay 1971; 71: 50-64.
7. Carod-Artal FJ. Stroke: a neglected complication of American trypanosomiasis (Chagas' disease). Trans R Soc Trop Med Hyg 2007; 101: 1075-1080.
8. Lowe GD. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2004; 33: 455-457.
9. Berra HH, Piaggio E, Revelli SS, et al. Blood viscosity changes in experimentally Trypanosoma cruzi-infected rats. Clin Hemorheol Microcirc 2005; 32: 175-182.
10. Salomone OA. Chagas' Cardiomyopathy and Thrombosis: the Beginning and the End of a Dangerous Affair. Rev Esp Cardiol 2003; 56: 333-334.
11. Carod-Artal FJ. Enfermedad de Chagas e Ictus. Neurología 2006; 21: 135-149.
12. Schuetz P, Christ-Crain M, Morgenthaler NG, et al. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007; 14: 345-351.
13. Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008; 28: 8-22.
14. Kreutz RP, Tantry US, Bliden KP, et al. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagulation and Fibrinolysis 2007; 18: 713-718.
15. Herrera RN, Diaz E, Pérez R, et al. The prothrombotic state in early stages of chronic Chagas' disease. Rev Esp Cardiol 2003; 56: 377-382.
16. Herrera RN, Diaz E, Perez Aguilar R, et al. Prothrombotic state in early stages of chronic Chagas' disease. Its association with thrombotic risk factors. Arch Cardiol Mex 2005; 75: 38-48.
17. Carod-Artal FJ, Fernandes da Silva TV, Vilela Nunes S, et al. Thrombophilia is not a predictive factor of stroke in Chagas Disease. Neurology 2004; 62: A240-A241.
18. World Health Organization (WHO). Chagas disease. Thirteenth Programme Report UNDP/TDR. Geneva, Switzerland 1997.
19. Riera C, Vergés M, López-Chejade P, et al. Desarrollo y evaluación de una técnica ELISA con antígeno crudo de Trypanosoma cruzi para el diagnóstico de la enfermedad de Chagas. Enf Emerg 2009; 11: 22-29.
20. Tobler LH, Contestable P, Pitina L, et al. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 2007; 47: 90-96.
21. Marcon GE, Andrade PD, de Albuquerque DM, et al. Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. Diagn Microbiol Infect Dis 2002; 43: 39-43.
22. Piron M, Fisa R, Casamitjana N, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop 2007; 103: 195-200.
23. StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: Stata- Corp LP.
24. Py M, Pedrosa R, Silveira J, et al. Neurological Manifestations in Chagas Disease without Cardiac Dysfunction: Correlation between Dysfunction of the Parasympathetic Nervous System and White Matter Lesions in the Brain. J Neuroimaging 2009; 19: 332-336.
25. Tanowitz HB, Burns ER, Sinha AK, et al. Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg 1990; 43: 274-281.
26. Schnittler HJ, Preissner KT. Vascular endothelium and infectious diseases: trick and treat. Thromb Haemost 2005; 94: 238-239.
27. Jong E, Louw S, van Gorp EC, et al. The effect of initiating combined antirretroviral therapy on endotelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010; 104: 1228-1234.
28. Fota-Markowska H, Modrzewska R, Krzowska-Firych J, et al. Concentration of prothrombin fragment 1 + 2 (f1 + 2) in patients with liver cirrhosis and chronic hepatitis C infection. Ann Univ Mariae Curie Sklodowska Med 2004; 59: 4-7.
29. Consolazio A, Borgia MC, Ferro D, et al. Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. Aliment Pharmacol Ther 2004; 1: 289-294.
30. Manucci PM. Mechanisms, markers and management of coagulation activation. Thrombosis 1993; 44: 851-870.
31. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 1992; 326: 242-250, 310-318.
32. Cançado JR. Long term evaluation of Chagas disease with Benznidazole. Rev Inst Med Trop Sao Paulo 2002; 44: 29-37.
33. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003; 19: 495-501.
34. Rodrigues Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97: 3-24.
35. Jackson Y, Chappuis F. Tolerance of Nifurtimox for the treatment of Chagas disease in adults. Enf Emerg 2009; 11: 49.
36. Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2011; 54: 4896-4899.
37. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144: 724-734.
38. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49: 1675-1684.